Optimum News

Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, … Continue reading “Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury”

By Optimum

Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy

HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple … Continue reading “Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy”

By Optimum

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Hamburg, Germany; Paris, France, 08 March 2018 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research … Continue reading “Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform”

By Optimum

Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018 Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., … Continue reading “Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec”

By Optimum

Optimum Appointed by Silence Therapeutics as Financial PR and Investor Relations Advisor in Europe & US

Significantly Expands Number of Healthcare Clients Since Launch 02 March 2018, London: Optimum Strategic Communications (Optimum), an international strategic healthcare communications and investor relations advisor, announces its appointment as investor … Continue reading “Optimum Appointed by Silence Therapeutics as Financial PR and Investor Relations Advisor in Europe & US”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH